.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,455,556

« Back to Dashboard

Details for Patent: 6,455,556

Title: Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
Abstract:The invention relates to the novel modifications B and C of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of the formula ##STR1## their use and pharmaceutical preparations comprising this crystal modifications.
Inventor(s): Portmann; Robert (Pratteln, CH), Hofmeier; Urs Christoph (St. Pantaleon, CH), Burkhard; Andreas (Basel, CH), Scherrer; Walter (Rheinfelden, CH), Szelagiewicz; Martin (Munchenstein, CH)
Assignee: Novartis AG (Basel, CH)
Filing Date:May 31, 2001
Application Number:09/871,366
Claims:1. A crystal modification B of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of the formula ##STR3##

having characteristic lines with interplanar spacings (d values) of 11.0 .ANG., 8.3 .ANG., 5.18 .ANG., 4.88 .ANG., 4.80 .ANG., 4.42 .ANG., 4.33 .ANG., 4.19 .ANG., 4.12 .ANG., 3.81 .ANG., 3.50 .ANG., 3.41 .ANG., 3.36 .ANG., 3.32 .ANG., 3.28 .ANG., 3.24 .ANG., 3.05 .ANG. and 2.83 .ANG., determined by means of an X-ray powder pattern.

2. A crystal modification according claim 1, which has an X-ray powder pattern having the following characteristic lines with interplanar spacings (d values) of 11.0 .ANG. (medium), 8.3 .ANG. (medium), 8.1 .ANG. (very weak), 5.18 .ANG. (very strong), 5.11 .ANG. (weak), 4.88 .ANG. (medium), 4.80 .ANG. (strong), 4.71 .ANG. (very weak), 4.61 .ANG. (weak), 4.45 .ANG. (weak), 4.42 .ANG. (strong), 4.33 .ANG. (very strong), 4.19 .ANG. (medium), 4.12 .ANG. (strong), 4.09 .ANG. (weak), 3.99 .ANG. (very weak), 3.95 .ANG. (very weak), 3.84 .ANG. (weak), 3.81 .ANG. (medium), 3.65 .ANG. (weak), 3.61 .ANG. (very weak), 3.58 .ANG. (very weak), 3.54 .ANG. (weak), 3.50 .ANG. (medium), 3.47 .ANG. (very weak), 3.41 .ANG. (medium), 3.36 .ANG. (very strong), 3.32 .ANG. (strong), 3.28 .ANG. (medium), 3.24 .ANG. (medium), 3.10 .ANG. (weak), 3.07 .ANG. (weak), 3.05 .ANG. (medium), 2.93 .ANG. (weak), 2.88 .ANG. (weak), 2.87 .ANG. (very weak), 2.83 .ANG. (medium), 2.66 .ANG. (weak), 2.63 .ANG. (very weak), 2.55 .ANG. (weak), 2.50 .ANG. (weak), 2.46 .ANG. (weak), 2.44 .ANG. (weak), 2.35 .ANG. (weak).

3. A crystal modification according to claim 1, having the following absorption in the FT-IR spectrum (KBr pellet--transmission method): 1678 cm.sup.-1.

4. A crystal modification according to claim 3, having the following absorptions in the FT-IR spectrum (KBr pellet--transmission method): 3404, 3199, 3125, 1678, 1635, 1560, 1475, 1393, 1357, 1322, 1286, 1237, 1051, 1036, 1028, 889, 837, 800, 719, 667 and 645 cm.sup.-1.

5. A crystal modification according to any one of claim 1, having the following absorptions in the FT-Raman spectrum (powder--reflection method 180.degree.): 3166, 3089, 2970, 1678, 1628, 1614, 1559, 1464, 1441, 1391, 1275, 1244, 1147, 1086, 1062, 1036, 1014, 839, 773, 724, 690, 668, 595, 549, 500, 493, 430 and 365 cm.sup.-1.

6. A crystal modification B according to any one of claim 1, having in the thermogram in differential scanning calorimetry a weak thermal signal at 205.degree. C. (180-220.degree. C.) in addition to an endothermic signal in the range from 230.degree. C. to 260.degree. C. (peak temperature 239-245.degree. C.).

7. A crystal modification C of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole4- carboxamide of the formula ##STR4##

having characteristic lines with interplanar spacings (d values) of 9.0 .ANG., 4.73 .ANG., 4.65 .ANG., 3.75 .ANG., 3.54 .ANG., 3.42 .ANG., 3.25 .ANG., determined by means of an X-ray powder pattern.

8. A crystal modification according to claim 7, having an X-ray powder pattern with the following characteristic lines with interplanar spacings (d values) of 9.0 .ANG. (medium), 7.0 .ANG. (weak), 5.49 .ANG. (weak), 5.11 .ANG. (very weak), 4.80 .ANG. (weak), 4.73 .ANG. (strong), 4.65 .ANG. (very strong), 4.47 .ANG. (very weak), 4.19 .ANG. (very weak), 4.11 .ANG. (very weak), 3.98 .ANG. (very weak), 3.83 .ANG. (very weak), 3.75 .ANG. (strong), 3.73 .ANG. (weak), 3.54 .ANG. (medium), 3.50 .ANG. (weak), 3.42 .ANG. (strong), 3.25 .ANG. (medium), 2.88 .ANG. (very weak), 2.80 .ANG. (very weak), 2.74 .ANG. (very weak), 2.67 .ANG. (very weak), 2.64 .ANG. (weak).

9. A crystal modification according to claim 7, having the following absorption in the infrared spectrum (KBr pellet--transmission method): 3137 cm.sup.-1.

10. A crystal modification according to claim 9, having the following absorptions in the infrared spectrum (KBr pellet--transmission method): 3396, 3287, 3137, 1657, 1631, 1602, 1559, 1475, 1392, 1323, 1287, 1237, 1122, 1104, 1047, 1035, 1012, 876, 839, 797, 773, 729 and 653 cm.sup.-1.

11. A crystal modification according to any one of claim 7, having the following absorptions in the FT-Raman spectrum (powder--reflection method 180.degree.): 3137, 3080, 3012, 2971, 1673, 1629, 1602, 1561, 1436, 1271, 1248, 1105, 1065, 1035, 1013, 839, 800, 767, 726, 690, 672, 593, 549, 500, 492, 435 and 370 cm.sup.-1.

12. A crystal modification C according to any one of claim 7, having in the thermogram in differential scanning calorimetry a very broad, weak, exothermic signal in the region of 180.degree. C., in addition to an endothermic signal in the range from 230.degree. C. to 260.degree. C. (peak temperature 239-245.degree. C).

13. A crystal modification B according to any one of claim 1 in essentially pure form.

14. A crystal modification C according to claim 7 in essentially pure form.

15. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of crystal modification B of the compound 1-(2,6- difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide according to claim 1.

16. A method of treating epilepsy comprising administering to subject in need of such treatment a therapeutically effective amount of crystal modification B of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide according to claim 1.

17. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of crystal modification C of the compound 1-(1,6- difluorobenzyl)-1H-1,2,3-trazole-4-carboxamide according to claim 7.

18. A method of treating epilepsy comprising administering to a subject in need of such treatment a therapeutically effective amount of crystal modification C of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide according to claim 7.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc